– FINLAND, Turku – Faron Pharmaceuticals Oy (LON: FARN), the clinical-stage biopharmaceutical company, today announced the appointment of Anne Whitaker to its Board as a Non-Executive Director following the AGM held today.
About Anne Whitaker
Anne Whitaker has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech, and specialty pharma companies. She is the current Chairman of the Board for Aerami Therapeutics Holdings, Inc. (formerly Dance Biopharm Holdings, Inc.), a private life science company. Before taking the role of Chairman at Aerami, Anne served as the CEO and a Director from October 2018 to November 2020. Anne served as CEO of Novoclem Therapeutics, Inc. from February 2017 until April 2018.
Before that, she served as EVP at Bausch Health overseeing its Global Branded Pharmaceutical Business and the Western European Region from May 2015 to January 2017. Previously, Anne served as President and CEO of Synta Pharmaceuticals. She also served as President, North America Pharmaceuticals at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations for the region and held several commercial leadership roles at GlaxoSmithKline.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently, in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndromes after an ischemia-reperfusion injury caused by major trauma. Faron is based in Turku, Finland.
For more information: https://www.faron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
